Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. However, few inhibitors for the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiessling, Michael K., Curioni-Fontecedro, Alessandra, Samaras, Panagiotis, Lang, Silvia, Scharl, Michael, Aguzzi, Adriano, Oldrige, Derek A., Maris, John M., Rogler, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731059/
https://www.ncbi.nlm.nih.gov/pubmed/26821351
http://dx.doi.org/10.1371/journal.pone.0147682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731059/
https://www.ncbi.nlm.nih.gov/pubmed/26821351
http://dx.doi.org/10.1371/journal.pone.0147682

Ejemplares similares